15.05.2019 12:58:12

J&J Plans To Execute All Levers Of Capital Allocation Strategy

(RTTNews) - Johnson & Johnson (JNJ) said that it plans to execute all levers of its capital allocation strategy to fund future growth opportunities while providing returns to shareholders. It plans to maximize potential of leading brands by filing more than 40 line extensions for regulatory approval through 2023.

The company noted that it will host a meeting today with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023.

The company plans to file for regulatory approval or launch at least 10 new medicines between 2019 and 2023.

Analysen zu Johnson & Johnsonmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Johnson & Johnson 139,26 0,32% Johnson & Johnson